8 Biotechnology Stocks to Buy Now

8 Biotechnology Stocks to Buy Now

This week, 8 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This is a strong week for Acceleron Pharma Inc (XLRN). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of XLRN stock.

This week, Inovio Pharmaceuticals, Inc. (INO) pushes up from a C to a B rating. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of INO stock.

Vital Therapies, Inc. (VTL) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Cytokinetics, Incorporated (CYTK) boosts its rating from a C to a B this week. Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of CYTK stock.

Exelixis, Inc.’s (EXEL) ratings are looking better this week, moving up to a A from last week’s B. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

The rating of Abeona Therapeutics, Inc. (ABEO) moves up this week, rising from a C to a B. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ABEO stock.

Amarin Corporation Plc Sponsored ADR (AMRN) gets a higher grade this week, advancing from a C last week to a B. Amarin Corporation Plc Sponsored ADR focuses on developing the treatment for cardiovascular disease in the field of lipid science. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

This week, Navidea Biopharmaceuticals, Inc.’s (NAVB) ratings are up from a C last week to a B. Navidea Biopharmaceuticals, Inc. is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of NAVB stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/8-biotechnology-stocks-to-buy-now-4/.

©2019 InvestorPlace Media, LLC